Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DNTH · as of Mar 31, 2025
Ownership Breakdown
102
Institutional Holders
▲ 6 vs Q4
$685.46M
Total Inst. Value
▼ $80.24M vs Q4
41.75M
Shares Outstanding
freeFloat 69.84%
37.72M
13F Shares Held
▲ 2.59M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DNTH largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 4.48M | 13.09% | 13.09% | $81.31B | May 12, 2025 | ▲ 43.3K |
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 2.87M | 8.37% | 8.37% | $52.00B | May 15, 2025 | ▲ 1.00M |
FAIRMOUNT FUNDS MANAGEMENT LLC pharmaceutical preparations | 2.70M | 7.89% | 7.89% | $48.99B | May 15, 2025 | — held |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC pharmaceutical preparations | 2.69M | 7.86% | 7.86% | $48.79B | May 15, 2025 | — held |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 2.36M | 6.89% | 6.89% | $42.77B | May 15, 2025 | NEW |
OCTAGON CAPITAL ADVISORS LP pharmaceutical preparations | 2.34M | 6.84% | 6.84% | $42.48B | May 16, 2025 | ▲ 231.5K |
VR ADVISER, LLC pharmaceutical preparations | 1.74M | 5.09% | 5.09% | $31.64B | May 15, 2025 | — held |
AVIDITY PARTNERS MANAGEMENT LP pharmaceutical preparations | 1.72M | 5.03% | 5.03% | $31.22B | May 15, 2025 | ▼ 1.15M |
VESTAL POINT CAPITAL, LP pharmaceutical preparations | 1.70M | 4.97% | 4.97% | $30.84B | May 15, 2025 | ▲ 625.1K |
BLACKROCK, INC. pharmaceutical preparations | 1.62M | 4.72% | 4.72% | $29.31B | May 2, 2025 | ▼ 35.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
17
Increased
+3.38M shares8
New Positions
first time holders13
Decreased
−2.99M shares0
Sold Out
fully exitedNet shares change (top 50)
+388.2K
+3.38M / −2.99M
Net new holders
+12
8 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DNTH insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
13
Buy transactions
11
Sell transactions
1.18
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Randhawa Simrat EVP, Head of R&D | Jun 1, 2026 | Sale | 5,428 | $89.72 | $487.0K | 25.1K | Form 4 ↗ |
Randhawa Simrat EVP, Head of R&D | Jun 1, 2026 | Sale | 16,943 | $90.72 | $1.54M | 8.2K | Form 4 ↗ |
Randhawa Simrat EVP, Head of R&D | Jun 1, 2026 | Sale | 4,159 | $91.37 | $380.0K | 4.0K | Form 4 ↗ |
Romano Steven J. director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Read Simon director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Lawton Alison Frances director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
McGeorge Anne director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
KANGO SUJAY director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Violin Jonathan director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Soteropoulos Paula director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Dianthus Therapeutics, Inc. (DNTH) is primarily owned by institutional investors, who hold approximately 90.3% of total shares outstanding. Company insiders own approximately 30.16%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Dianthus Therapeutics, Inc. is FMR LLC, holding approximately 4.48 million shares — equal to 13.09% of outstanding shares — as of March 31, 2025.
A total of 102 institutional investors currently hold DNTH stock, with a combined institutional value of approximately $685,462,200 as of the most recent 13F filing period.
Frequently asked questions
DNTH ownershipDianthus Therapeutics, Inc. (DNTH) is primarily owned by institutional investors, who hold approximately 90.3% of shares. The largest shareholder is FMR LLC with a 13.09% stake. Company insiders hold 30.16%. Data sourced from SEC Form 13F as of March 31, 2025.